DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of the study drug, DS-3201b, given in combination with
irinotecan to people who have recurrent small cell lung cancer (SCLC).